Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature

Table 1

Summary of reported uses of daratumumab in PBL.

Reference	HIV status	EBV status	Stage	Lines of tx before Dara	Prior SCT	Dara regimen	Outcome
Suarez et al. [31]	—	—	IV	0	n/a	Dara + CHOP	PD
Chikeka et al. [32]	+	+	IV	1	n/a	Dara + V + DHAP	CR-ASCT
Marvyin et al. [33]	—	n/a		0		Dara + CHOP	PD
Kathrotiya et al. [34]	—	+	IV	2	ASCT	Dara + VR	CR-AlloSCT
Raychaudhari et al. [25]	—	—	IV	2	n/a	DRD + carfilzomib	PD-CAR-T
Roché et al. [35]	—	—	IV	4	ASCT	Dara alone	PD
Roché et al. [35]	—	+	II	2	n/a	Dara alone	PD
Roché et al. [35]	—	—	II	1	ASCT	Dara alone	PD
Ricker et al. [37]	—	+	IV	0	n/a	Dara + EPOCH	CR
Ricker et al. [37]	+	+	IV	0	n/a	Dara + EPOCH	CR
Ricker et al. [37]	—	+	IV	0	n/a	Dara + EPOCH	CR
Ricker et al. [37]	—	—	IV	0	n/a	Dara + EPOCH	PD

CHOP, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone; V, bortezomib; DHAP, dexamethasone, cytarabine, and cisplatin; VR, bortezomib, rituximab; PD, progressive disease; CR, complete response.